Treatment and Outcome in Muscle Invasive Bladder Cancer: a Population-based Survey

Overview

Journal World J Urol

Specialty Urology

Date 2010 Apr 13

PMID 20383640

Citations 6

Authors

Anna M Leliveld

Benjamin H J Doornweerd

Esther Bastiaannet

Michael Schaapveld

Igle J de Jong

Affiliations

Soon will be listed here.

Abstract

Objective: To assess treatments and survival of patients with muscle invasive bladder cancer (MIBC) in the Comprehensive Cancer Center Northern Netherlands (CCCN) region.

Study Design And Setting: Retrospective cohort analysis. Data of 548 patients with MIBC diagnosed between 1997 and 2002 were collected from the CCCN cancer registry. All had a follow-up of at least 5 years. Logistic regression analysis on treatments as well as survival analysis was performed.

Results: The treatments were radical cystectomy in 205/548 (37.5%) patients. TUR plus radiotherapy in 246 (44.9%) and palliation in 97 (17.7%). Multivariate analysis identified TNM stage (P < 0.0001) and age (P < 0.0001) as independent variables for cystectomy. Hospital type and year of diagnosis were not significant different between patients treated by cystectomy versus other type of treatment. TNM stage (P < 0.0001), age (P = 0.0043), and comorbidity (P = 0.0028) were independent variables for disease-specific survival (DSS) after cystectomy.

Conclusion: In the CCCN region, only 1/3 of patients with MIBC were treated with radical cystectomy. TNM stage and age were identified as main variables for the choice for cystectomy. TNM stage, age, and comorbidity were independent variables for disease-specific survival after cystectomy.

Citing Articles

Impact of salvage cytotoxic chemotherapy on prognosis in patients with recurrence after radical cystectomy: a multi-institutional retrospective study.

Koguchi D, Matsumoto K, Ikeda M, Taoka Y, Hirayama T, Murakami Y BMC Urol. 2022; 22(1):75.

PMID: 35549909 PMC: 9103293. DOI: 10.1186/s12894-022-01026-3.

Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.

van Hoogstraten L, Witjes J, Meijer R, Ripping T, Kiemeney L, Aben K BJU Int. 2022; 130(6):764-775.

PMID: 35064953 PMC: 9790563. DOI: 10.1111/bju.15697.

Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer.

Abudurexiti M, Xie H, Jia Z, Zhu Y, Zhu Y, Shi G Front Oncol. 2019; 9:856.

PMID: 31552180 PMC: 6743371. DOI: 10.3389/fonc.2019.00856.

Bladder preservation by concurrent chemoradiation for muscle-invasive bladder cancer: Applicability in low-income countries.

Khader J, Farah N, Salem A Rep Pract Oncol Radiother. 2013; 16(5):178-83.

PMID: 24376977 PMC: 3863137. DOI: 10.1016/j.rpor.2011.04.003.

Gender-dependent cancer-specific survival following radical cystectomy.

May M, Stief C, Brookman-May S, Otto W, Gilfrich C, Roigas J World J Urol. 2011; 30(5):707-13.

PMID: 21984471 DOI: 10.1007/s00345-011-0773-1.

References

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

van Rhijn B, Burger M, Lotan Y, Solsona E, Stief C, Sylvester R . Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56(3):430-42. DOI: 10.1016/j.eururo.2009.06.028. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Sobin L, FLEMING I . TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997; 80(9):1803-4. DOI: 10.1002/(sici)1097-0142(19971101)80:9<1803::aid-cncr16>3.0.co;2-9. View

Figueroa A, Stein J, Dickinson M, Skinner E, Thangathurai D, Mikhail M . Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer. 1998; 83(1):141-7. DOI: 10.1002/(sici)1097-0142(19980701)83:1<141::aid-cncr19>3.0.co;2-x. View

Clark P, Stein J, Groshen S, Cai J, Miranda G, Lieskovsky G . Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer. 2005; 104(1):36-43. DOI: 10.1002/cncr.21126. View

Prout Jr G, Wesley M, Yancik R, Ries L, Havlik R, Edwards B . Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005; 104(8):1638-47. DOI: 10.1002/cncr.21354. View

Mungan N, Aben K, Schoenberg M, Visser O, Coebergh J, Witjes J . Gender differences in stage-adjusted bladder cancer survival. Urology. 2000; 55(6):876-80. DOI: 10.1016/s0090-4295(00)00523-9. View

Ghoneim M, Abol-Enein H . Lymphadenectomy with cystectomy: is it necessary and what is its extent?. Eur Urol. 2004; 46(4):457-61. DOI: 10.1016/j.eururo.2004.06.010. View

10.

Lodde M, Palermo S, Comploj E, Signorello D, Mian C, Lusuardi L . Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur Urol. 2005; 47(6):773-8. DOI: 10.1016/j.eururo.2005.01.017. View

11.

Hamel M, Henderson W, Khuri S, Daley J . Surgical outcomes for patients aged 80 and older: morbidity and mortality from major noncardiac surgery. J Am Geriatr Soc. 2005; 53(3):424-9. DOI: 10.1111/j.1532-5415.2005.53159.x. View

12.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

13.

Mills R, Turner W, Fleischmann A, Markwalder R, Thalmann G, Studer U . Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol. 2001; 166(1):19-23. View

14.

Nieuwenhuijzen J, Pos F, Moonen L, Hart A, Horenblas S . Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol. 2005; 48(2):239-45. DOI: 10.1016/j.eururo.2005.03.022. View

15.

Bochner B, Kattan M, Vora K . Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006; 24(24):3967-72. DOI: 10.1200/JCO.2005.05.3884. View

16.

Dalbagni G, Genega E, Hashibe M, Zhang Z, Russo P, Herr H . Cystectomy for bladder cancer: a contemporary series. J Urol. 2001; 165(4):1111-6. View

17.

Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R . Patterns of care for the treatment of bladder cancer. J Urol. 2003; 169(5):1697-701. DOI: 10.1097/01.ju.0000056727.30546.b7. View

18.

Karakiewicz P, Shariat S, Palapattu G, Gilad A, Lotan Y, Rogers C . Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006; 176(4 Pt 1):1354-61. DOI: 10.1016/j.juro.2006.06.025. View

19.

Visser O, Nieuwenhuijzen J, Horenblas S . Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater amsterdam. J Urol. 2005; 174(1):97-102. DOI: 10.1097/01.ju.0000162055.58405.96. View

20.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008; 54(2):303-14. DOI: 10.1016/j.eururo.2008.04.051. View